Safety is the first question every parent asks. This page gives you an honest, evidence-based picture of what the research actually shows — common effects, rare risks, how they are monitored, and what the decades of clinical data tell us.
Recombinant human growth hormone (somatropin) has been FDA-approved for use in children since 1985 — making it one of the longest-studied pediatric hormonal treatments available. Large post-marketing safety registries, including the KIGS database tracking over 83,000 patients and the GeNeSIS program, have generated an extensive body of safety data across decades of real-world use.
The overall safety profile is well-established. Serious adverse events are uncommon. The decision to treat is made by a licensed physician who carefully evaluates the individual clinical picture, including any factors that may increase risk.
At our partner clinics, regular physician follow-up — typically every 3–6 months — is a non-negotiable part of treatment. Blood work, bone age assessment, height velocity measurement, and clinical examination occur at every visit. This is not optional: active monitoring is how potential side effects are caught early and how dosing is adjusted appropriately throughout treatment.
These effects are reported by a meaningful subset of patients and are generally manageable:
Redness, soreness, or mild bruising at the injection site is the most frequently reported side effect. Rotating injection sites and proper injection technique reduce this significantly. Most children adapt quickly.
Some children experience headaches during the initiation phase or after dose increases. Usually resolves within days to weeks. Persistent or severe headaches should be reported to the physician promptly as they can rarely indicate a more significant issue.
Mild swelling in the hands or feet, particularly in adolescents. Growth hormone promotes fluid balance, and some temporary fluid retention is common at initiation. Typically resolves on its own or with minor dose adjustment.
Mild joint or muscle discomfort (arthralgias, myalgias) is occasionally reported, particularly during periods of rapid dose increase. Generally mild and self-limiting.
These side effects are less frequent but are specifically monitored for at every follow-up visit:
A condition where the ball of the hip joint slips off the thigh bone at the growth plate. SCFE has an elevated occurrence in children on growth hormone, particularly those who are overweight or have rapid growth. Warning signs include a limp or hip, knee, or thigh pain — report these to the physician immediately. Surgically correctable when identified early.
Rare increase in pressure within the skull, typically presenting as severe headache, nausea, vision changes, or papilledema. Usually occurs early in treatment. Resolves with dose reduction or temporary discontinuation. Routine eye exams are recommended as a monitoring measure.
Growth hormone has physiological effects on insulin sensitivity. Blood glucose is monitored throughout treatment. Children with a family history of diabetes or pre-existing metabolic concerns are monitored more closely. Clinical diabetes as a direct result of GH therapy in otherwise healthy children is rare.
Rapid growth can accelerate underlying scoliosis. Children with known or suspected scoliosis are monitored carefully. Spinal curvature screening is part of routine follow-up for children with rapid growth velocity on therapy.
This is the concern parents ask about most. The data is reassuring:
Several concerns circulate online that are not supported by clinical evidence in pediatric patients treated within standard protocols:
At our partner clinics, active monitoring throughout treatment includes:
This is why the physician relationship is central to safe treatment — not just to start therapy, but to actively manage it throughout your child's growth years.
Have more questions about safety, side effects, or whether your child may be a candidate for evaluation? Our care coordinators are here to help — no cost, no obligation.
Medical Disclaimer: HGHKids.com is a privately operated educational and referral platform. We do not diagnose, treat, or prescribe. All medical decisions are made by licensed physicians following appropriate evaluation. Information on this site is for educational purposes only and does not constitute medical advice.